



Demise of Director Dr. John Chiplin

NEW YORK and SYDNEY, Australia, 31 July, 2024 – It is with great sadness that the Board of Beroni Group (OTCQB: BNIGF; NSX: BTG) (“Beroni” or the “Company”) announces the passing of Dr. John Chiplin, non-executive director of the Company.

John was a highly respected Board member over the two years he was with the Company. The Board extends their deepest sympathy to John’s family, friends and colleagues.

-End-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For more information, please contact us at:

Tel: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com